studies

mBC - TNBC - L1 - PDL1 positive, atezolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94] 0.71[0.54; 0.94]IMpassion-130 (PDL1>1%), 201810%369NAnot evaluable PFS (extension)detailed resultsIMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80] 0.63[0.50; 0.80]IMpassion-130 (PDL1>1%), 201810%369NAnot evaluable progression or deaths (PFS)detailed resultsIMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78] 0.62[0.49; 0.78]IMpassion-130 (PDL1>1%), 201810%369NAnot evaluable DORdetailed resultsIMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85] 0.60[0.42; 0.85]IMpassion-130 (PDL1>1%), 201810%369NAnot evaluable objective responses (ORR)detailed resultsIMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98] 1.96[1.29; 2.98]IMpassion-130 (PDL1>1%), 201810%369NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 01:58 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 143 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons